Virtual Library

Start Your Search

Martin Paradelo



Author of

  • +

    EP1.03 - Biology (ID 193)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Biology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.03-23 - Update of the Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC (Now Available) (ID 1858)

      08:00 - 18:00  |  Author(s): Martin Paradelo

      • Abstract
      • Slides

      Background

      Current evidence highlights the potential role of tumor-infiltrating lymphocytes (TILS) as a prognostic factor in many types of tumors; in non-small cell lung cancer (NSCLC), this relationship is not well determined. TILs are being studied with different methods such as immunohistochemistry and optical microscopy. The primary endpoint is to identify TILS in patients with NSCLC, classified as present or absent, and its relation to progression free survival (PFS).

      Method

      Retrospective and analytical case study of Instituto Oncológico de Córdoba. 187 patients with stage IIIB and IV NSCLC were analyzed. TILS are descriptively classified as present or absent. Survival curves were calculated using the Kaplan-Meier method.

      Result

      63% of patients had adenocarcinoma and 37% squamous cell carcinoma. 72% were men. 82% were smokers. 65% of patients with squamous histology and % 58 with adenocarcinoma, showed TILS. Patients with adenocarcinoma with TILS present had higher PFS 13.3 months, compared to patients with absent, 8.8 months. These differences were statistically significant (PFS: p=0.004). The patients with squamous cell carcinoma with TILS had 10.8 months PFS. Those who had infiltrated absent had a PFS of 5.6 months. These differences were also statistically significant (PFS: 0.001).

      Conclusion

      Our study shows that patients whose pathological samples presented inflammatory infiltrate had higher PFS. The presence of TILS could be used as an important prognostic factor in this patient population.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.